Pilot study of NKTR214 and nivolumab in patients with sarcomas.

Sandra P. D'Angelo,Anthony Paul Conley,Ciara Marie Kelly,Mark A. Dickson,Mrinal M. Gounder,Ping Chi,Mary-Louise Keohan,J. Andrew Livingston,Shreyaskumar Patel,Travis Adamson,Hannah Kiesler,Matthew Biniakewitz,Haley Phelan,Mercedes M. Condy,Narasimhan P. Agaram,Li-Xuan Qin,Joseph P. Erinjeri,Sinchun Hwang,William D. Tap

Pilot study of NKTR214 and nivolumab in patients with sarcomas.

2019

Sandra P. D'Angelo
Anthony Paul Conley
Ciara Marie Kelly
Mark A. Dickson
Mrinal M. Gounder
Ping Chi
Mary-Louise Keohan
J. Andrew Livingston
Shreyaskumar Patel
Travis Adamson
Hannah Kiesler
Matthew Biniakewitz
Haley Phelan
Mercedes M. Condy
Narasimhan P. Agaram
Li-Xuan Qin
Joseph P. Erinjeri
Sinchun Hwang
William D. Tap

11010Background: Monotherapy checkpoint inhibitors have minimal efficacy in most patients with metastatic sarcoma. NKTR-214 is a CD122-preferential IL-2 pathway agonist that activates and expands n...

Keywords:

Internal medicine
Sarcoma
Oncology
Agonist
Nivolumab
Pathology
Medicine
metastatic sarcoma
immune checkpoint inhibitors
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations